Spark Therapeutics, Inc. (NASDAQ:ONCE) – Stock analysts at Leerink Swann increased their Q3 2017 earnings estimates for Spark Therapeutics in a research note issued on Tuesday. Leerink Swann analyst J. Schwartz now forecasts that the biotechnology company will earn ($1.64) per share for the quarter, up from their previous estimate of ($1.96). Leerink Swann also issued estimates for Spark Therapeutics’ Q4 2017 earnings at ($1.64) EPS, FY2017 earnings at ($7.31) EPS and FY2018 earnings at ($4.56) EPS.

Spark Therapeutics (NASDAQ:ONCE) last issued its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($1.89) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.75) by ($0.14). The business had revenue of $1.48 million during the quarter, compared to analyst estimates of $1.33 million. Spark Therapeutics had a negative net margin of 962.72% and a negative return on equity of 59.74%. The company’s revenue was up 14.7% on a year-over-year basis. During the same quarter last year, the firm posted ($1.04) earnings per share.

COPYRIGHT VIOLATION NOTICE: “Leerink Swann Analysts Raise Earnings Estimates for Spark Therapeutics, Inc. (ONCE)” was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this report on another website, it was copied illegally and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this report can be accessed at https://www.americanbankingnews.com/2017/10/12/leerink-swann-analysts-raise-earnings-estimates-for-spark-therapeutics-inc-once.html.

A number of other research firms also recently issued reports on ONCE. Cantor Fitzgerald reiterated a “buy” rating on shares of Spark Therapeutics in a research report on Friday, August 25th. William Blair started coverage on shares of Spark Therapeutics in a research report on Wednesday, June 28th. They issued an “outperform” rating for the company. ValuEngine upgraded shares of Spark Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, June 20th. Chardan Capital upgraded shares of Spark Therapeutics from a “neutral” rating to a “buy” rating and increased their target price for the stock from $60.00 to $100.00 in a research report on Tuesday, August 8th. Finally, BidaskClub upgraded shares of Spark Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, August 26th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and seventeen have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $88.38.

Shares of Spark Therapeutics (ONCE) opened at 86.20 on Thursday. The stock’s market capitalization is $2.69 billion. Spark Therapeutics has a 52 week low of $35.07 and a 52 week high of $91.00. The stock’s 50 day moving average is $85.91 and its 200 day moving average is $85.91.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. FMR LLC boosted its position in shares of Spark Therapeutics by 0.9% during the 1st quarter. FMR LLC now owns 4,656,655 shares of the biotechnology company’s stock valued at $248,386,000 after acquiring an additional 40,698 shares in the last quarter. Balyasny Asset Management LLC boosted its position in shares of Spark Therapeutics by 104.8% during the 2nd quarter. Balyasny Asset Management LLC now owns 59,400 shares of the biotechnology company’s stock valued at $3,549,000 after acquiring an additional 30,400 shares in the last quarter. Victory Capital Management Inc. boosted its position in shares of Spark Therapeutics by 1.2% during the 2nd quarter. Victory Capital Management Inc. now owns 417,410 shares of the biotechnology company’s stock valued at $24,936,000 after acquiring an additional 4,750 shares in the last quarter. Bank of New York Mellon Corp boosted its position in shares of Spark Therapeutics by 10.9% during the 1st quarter. Bank of New York Mellon Corp now owns 111,043 shares of the biotechnology company’s stock valued at $5,923,000 after acquiring an additional 10,916 shares in the last quarter. Finally, Russell Investments Group Ltd. boosted its position in shares of Spark Therapeutics by 81.6% during the 2nd quarter. Russell Investments Group Ltd. now owns 25,228 shares of the biotechnology company’s stock valued at $1,507,000 after acquiring an additional 11,335 shares in the last quarter. Institutional investors own 77.84% of the company’s stock.

In other Spark Therapeutics news, Director Anand Mehra sold 211,858 shares of the firm’s stock in a transaction on Monday, July 24th. The shares were sold at an average price of $70.15, for a total value of $14,861,838.70. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CFO Stephen W. Webster sold 2,337 shares of the firm’s stock in a transaction on Monday, July 31st. The stock was sold at an average price of $71.12, for a total transaction of $166,207.44. Following the completion of the sale, the chief financial officer now owns 4,837 shares in the company, valued at $344,007.44. The disclosure for this sale can be found here. Insiders sold a total of 1,333,195 shares of company stock worth $109,070,506 over the last 90 days. Company insiders own 7.30% of the company’s stock.

Spark Therapeutics Company Profile

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Earnings History and Estimates for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.